NDAORALCAPSULEPriority Review
Approved
Apr 2020
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
KOSELUGO (selumetinib) by AstraZeneca is mitogen-activated protein kinase kinase 1 inhibitors [moa]. Approved for neurofibromatosis type 1, plexiform neurofibroma. First approved in 2020.
Drug data last refreshed 20h ago
Mechanism of Action
Mitogen-Activated Protein Kinase Kinase 1 Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications (2)
Worked on KOSELUGO at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.